T. Rowe Price Investment Management Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

T. Rowe Price Investment Management Inc. grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,509,332 shares of the medical equipment provider's stock after buying an additional 435,445 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 2.17% of Lantheus worth $135,025,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. State of New Jersey Common Pension Fund D raised its position in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC raised its position in shares of Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. increased its holdings in Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares during the period. Foundry Partners LLC increased its holdings in Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 133 shares during the period. Finally, UMB Bank n.a. increased its holdings in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $1.23 during midday trading on Tuesday, hitting $103.93. The company had a trading volume of 643,614 shares, compared to its average volume of 954,035. Lantheus Holdings, Inc. has a 12-month low of $65.76 and a 12-month high of $126.89. The company has a market cap of $7.12 billion, a price-to-earnings ratio of 17.29 and a beta of 0.20. The company has a fifty day moving average of $97.80 and a two-hundred day moving average of $95.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last quarter. 1.50% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.